Gonadotropin-releasing Hormone Analog Cotreatment For The Preservation Of Ovarian Function During Gonadotoxic Chemotherapy For Breast Cancer: A Meta-analysis

OBJECTIVE: To determine whether gonadotropin-releasing hormone (GnRH)analog cotreatment with chemotherapy for breast cancer provides better reproductiveoutcomes for women at risk of premature ovarian failure (POF) as a side-effect ofgonadotoxic chemotherapy by meta-analysis.METHODS: Randomized controlled trials(RCTs) comparing GnRH cotreatmentwith chemotherapy alone in premenopausal women in the following electronicdata-bases: Pubmed, MEDLINE(OVID), CENTRAL(The Coehrane Central Registerof Controlled Trials), CBM, CNKI, VIP, and Wanfang data base were searched. Allthe data were analyzed by Stata11.2.RESULTS: Seven studies involving a total of677participants met the inclusioncriteria. The outcomes of meta-analysis implied that: Compared with adjuvantchemotherapy alone, the incidence of spontaneous menstruation demonstrated astatistically significant difference in favor of the GnRH cotreatment (OR2.83;95%CI,1.52-5.25).CONCLUSIONS: Evidence from RCTs suggests a potential benefit of GnRHcotreatment with chemotherapy in premenopausal women, with higher rates ofspontaneous resumption of menses.